StreetInsider.com News Articles

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech Announces Second Quarter 2026 Financial Results

Thu, 27 Aug 2026 17:05:00 -0400

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.

Second Quarter 2026 Financial Highlights:

Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including initial sales activity as commercial and distribution channels continued to develop. Revenue in the prior-year period consisted entirely

Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium

Tue, 25 Aug 2026 07:25:00 -0400

WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.

U.S. FDA 510(k) cleared and Health Canada approved revyve® Antimicrobial Wound Gel Spray WINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference review and related follow-up discussions. MHSRS is the premier scientific meeting focused on military medicine and medical research supporting military personnel and operational readiness.